1K9 Stock Chart & Stats
€43.00
€0.00(0.00%)
At close: 4:00 PM EDT
€43.00
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€11.12 - €44.40
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€2.27B
Enterprise Value€1.17K
Total Cash (Recent Filing)€373.64M
Total Debt (Recent Filing)€19.25M
Price to Earnings (P/E)23.6
Beta0.55
Next Earnings
Nov 10, 2026EPS Estimate
0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.15
Shares Outstanding51,734,222
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)3.31
Price to Sales (P/S)2.64
P/FCF Ratio27.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€44.09Price Target Upside2.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)1.04
Revenue Forecast (FY)€427.35M
Bulls Say, Bears Say
Bulls Say
Guidance And Testing GrowthRaised revenue and testing-volume guidance indicates expanding utilization of CareDx’s diagnostic platform and stronger demand across its testing portfolio. If achieved, this scale can support operating leverage, reinforce relationships with transplant centers, and provide a durable foundation for growth over the next several quarters.
Strong Balance Sheet And Cash GenerationA debt-free balance sheet with substantial cash and recent operating cash generation gives CareDx flexibility to fund clinical development, commercial expansion, and integration without relying heavily on external financing. This financial capacity also improves resilience if operating conditions or reimbursement timing become less favorable.
Coverage And Clinical ValidationBroader Medicare coverage reduces reimbursement uncertainty for important transplant tests and creates a clearer pathway for future organ expansions. Supporting clinical evidence strengthens the case for longitudinal molecular monitoring, which can improve physician adoption and encourage repeat testing over time.
Bears Say
Inconsistent Historical ProfitabilityThe recent return to profitability is encouraging, but repeated losses across prior periods make the current earnings level less proven. Continued execution is necessary to demonstrate that improved margins and earnings reflect a sustainable operating model rather than another temporary improvement in a volatile financial history.
High Operating Expense BaseOperating expenses are expected to consume a large portion of revenue, limiting near-term conversion of sales growth into durable operating profit. High spending may support expansion, but it also leaves less margin for execution mistakes and makes future profitability more dependent on achieving the company’s growth assumptions.
NavDx Integration And Margin RiskThe NavDx acquisition adds growth potential but introduces execution demands across systems, billing, and commercialization. Lower specialty-oncology ASPs and margins than the transplant business could dilute consolidated profitability until integration improves workflows, reimbursement, and test economics.
CareDx News
1K9 FAQ
What was CareDx’s price range in the past 12 months?
CareDx lowest stock price was €11.12 and its highest was €44.40 in the past 12 months.
What is CareDx’s market cap?
CareDx’s market cap is €2.27B.
When is CareDx’s upcoming earnings report date?
CareDx’s upcoming earnings report date is Nov 10, 2026 which is in 64 days.
How were CareDx’s earnings last quarter?
CareDx released its earnings results on Jul 30, 2026. The company reported €0.32 earnings per share for the quarter, beating the consensus estimate of €0.2 by €0.119.
Is CareDx overvalued?
According to Wall Street analysts CareDx’s price is currently Undervalued.
Does CareDx pay dividends?
CareDx does not currently pay dividends.
What is CareDx’s EPS estimate?
CareDx’s EPS estimate is 0.22.
How many shares outstanding does CareDx have?
CareDx has 51,734,222 shares outstanding.
What happened to CareDx’s price movement after its last earnings report?
CareDx reported an EPS of €0.32 in its last earnings report, beating expectations of €0.2. Following the earnings report the stock price went up 16.993%.
Which hedge fund is a major shareholder of CareDx?
Currently, no hedge funds are holding shares in DE:1K9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CareDx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€44.09 (2.53% Upside)
€44.09 (2.53% Upside)
Blogger Sentiment
Neutral
DE:1K9 Sentiment 67%
Sector Average 60%
Sector Average 60%
Insider Transactions
Sold Shares
Worth €3.3M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
288.39%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
19.97%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
CareDx
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
1K9 Company Deck
1K9 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong organic and inorganic growth, material margin expansion, a fortified balance sheet, and substantive clinical and reimbursement milestones (Medicare LCD, KOAR data, AlloHeme and HistoMap publications). Key near-term risks include sizable operating expense run-rate, material out-of-period revenue that inflated reported margins this quarter, and execution/integration risk around the NavDx acquisition and specialty oncology ASP/margin improvement. Management raised 2026 guidance while taking a conservative approach to NavDx assumptions and flagged potential modest near-term investments that could temper margin expansion. Overall, the positives around revenue growth, cash position, clinical evidence, and coverage developments outweigh the operational and integration cautions.View all DE:1K9 earnings summaries1K9 Stock 12 Month Forecast
Average Price Target
€44.09
▲(2.53% Upside)